23andMe Investor Day Presentation Deck

Future of 23andMe • Continuing to be world leader in direct-to-consumer personal genetic health services, growing annually Pioneering a genetics-based primary care service that empowers individuals to be proactive with their health Developing a pipeline of over 40 clinical and research stage programs addressing targets validated by human genetics • Leveraging strong balance sheet to support investment in therapeutics portfolio and strategic initiatives in DTC personal health services Copyright © 2022 23andMe, Inc. 23andMe® 77

View entire presentation